Clinical trials: Feeding and Eating Disorders
Binge Eating Disorder
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
To evaluate maintenance of efficacy based on time to relapse between SPD489 (50 or 70mg) and placebo, as measured by the number of binge days (defined as days during which at least 1 binge episode occurs) per week as assessed by…
- Trial name
- NCT02009163
- Testing
- Lisdexamfetamine dimesylate
- Where
- 53 sites in United States, Canada and 3 more
- Volunteers
- 418 people
- Sponsor
- Shire
Binge Eating Disorder
Open Label Extension in Adults With Binge Eating Disorder (BED)
To evaluate the safety and tolerability of SPD489 administered as a daily morning dose (50 or 70mg) in the treatment of moderate to severe binge eating disorder (BED) in adults
- Trial name
- NCT01657019
- Testing
- Lisdexamfetamine dimesylate
- Where
- 89 sites in United States, Germany and 1 more
- Volunteers
- 604 people
- Sponsor
- Shire
Binge Eating Disorder
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A study to evaluate a drug (dasotraline) on the safety, effectiveness and how well the body tolerates it, in adults with moderate to severe binge eating disorder
- Trial name
- NCT03107026
- Testing
- dasotraline 4mg, dasotraline 6mg
- Where
- 50 sites in United States
- Volunteers
- 491 people
- Sponsor
- Sumitomo Pharma America, Inc.
Binge Eating Disorder, Obesity
A Study to Examine the Efficacy and Safety of Meridia® (Sibutramine Hydrochloride) in Binge-Eating Disorder
The purpose of this study is to examine the safety and efficacy of sibutramine in preventing binge eating episodes. Additionally the study aim is to evaluate the safety and efficacy of sibutramine in reducing body weight in…
- Trial name
- NCT00402584
- Testing
- sibutramine
- Volunteers
- 304 people
- Sponsor
- Abbott
Type 1 Diabetes, Eating Disorders
Eating Disorders in Type 1 Insulin-dependent Diabetes Patients
The purpose of this study is to determine the prevalence of eating disorders in type 1 insulin-dependent diabetes patients
- Trial name
- Diaboulimia (NCT04506216)
- Testing
- cohort
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Icadom
Anorexia Nervosa
Exploring Clinical Study Experiences of People With Anorexia Nervosa
The study seeks to delve into the firsthand experiences of patients diagnosed with anorexia nervosa who partake in a separate clinical trial featuring a specific medical intervention.
- Trial name
- NCT06207890
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Eating Disorders, Binge Eating
Study of Efficacy and Safety of WELT-ED for Eating Disorder (WCTP-ED-B-01)
The purpose of this clinical trial is to evaluate the safety and efficacy of a digital therapeutic device (WELT-ED) based on Cognitive Behavioral Therapy (CBT) for the treatment of eating disorders.
- Conditions
- Eating Disorders, Binge Eating, Binge-Eating Disorder
- Trial name
- NCT06294353
- Testing
- WELT-ED (CBT based DTx), Standard Treatment
- Where
- 2 sites in South Korea
- Volunteers
- 134 people
- Sponsor
- WELT corp
Binge-Eating Disorder
EXOMIND (BTL-995) for Reduction of Binge-eating
The goal of this clinical trial is to evaluate if the treatment with the BTL-995-rTMS device is able to reduce binge eating in adults above the age of 22 years.
- Trial name
- NCT06910592
- Testing
- Treatment with BTL-995-rTMS
- Where
- Bulgaria
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- BTL Industries Ltd.
Binge Eating Disorder
Dasotraline Binge Eating Disorder Study
Evaluate the efficacy of flexibly-dosed dasotraline compared with placebo in adults with moderate to severe Binge Eating Disorder (BED)
- Trial name
- NCT02564588
- Testing
- Dasotraline
- Where
- 43 sites in United States
- Volunteers
- 319 people
- Sponsor
- Sumitomo Pharma America, Inc.
Binge Eating Disorder
Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder
To evaluate the efficacy of SPD489 compared to placebo in the treatment of moderate to severe binge eating disorder as measured by the number of binge days per week
- Trial name
- BED (NCT01291173)
- Testing
- lisdexamfetamine dimesylate (SPD489)
- Where
- 31 sites in United States
- Volunteers
- 271 people
- Sponsor
- Shire